Alvotech Enters Supply Agreements with Sandoz for Biosimilars
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 02 2026
0mins
Should l Buy ALVO?
Source: Newsfilter
- Strategic Partnership: Alvotech has signed supply and commercialization agreements with Sandoz covering multiple biosimilar candidates, aimed at paving the way for commercialization in global markets and further advancing Alvotech's strategic objectives.
- Market Coverage: The agreement includes one ophthalmology biosimilar candidate in Canada and three biosimilar candidates in immunology and gastroenterology in Australia and New Zealand, showcasing Alvotech's extensive market reach.
- Clear Responsibility Allocation: Under the agreements, Sandoz will handle regulatory submissions and commercial activities in their respective regions, while Alvotech focuses on development and manufacturing, ensuring product quality and supply stability.
- Enhanced Patient Access: This collaboration aims to support broad patient access following regulatory approvals, with Sandoz's strong market presence facilitating sustainable and affordable access to biologic medicines, thereby improving patient quality of life.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALVO
Wall Street analysts forecast ALVO stock price to rise
4 Analyst Rating
3 Buy
0 Hold
1 Sell
Moderate Buy
Current: 3.110
Low
5.00
Averages
8.75
High
10.00
Current: 3.110
Low
5.00
Averages
8.75
High
10.00
About ALVO
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alvotech Q4 2025 Earnings Call Highlights
- Financial Performance Boost: In Q4 2025, total revenues reached $173 million, a 13% year-over-year increase, with licensing revenues comprising 75%, driving gross margin up to 66% and adjusted EBITDA to $69 million, showcasing success in capital market transactions.
- Pipeline Expansion: Alvotech currently has 30 biosimilars in development and plans to establish a second manufacturing site with a U.S.-based CMO partner to enhance supply chain flexibility and resilience, ensuring future product availability in the market.
- Market Expansion Strategy: The collaboration with Teva to launch Selarsdi marks the company's second biosimilar launch in the U.S., while approvals for golimumab, denosumab, and aflibercept across Europe, the UK, and Japan further broaden market reach.
- Optimistic Outlook: Management reaffirmed the 2026 revenue guidance of $650 million to $700 million, expecting continued double-digit sales growth, with adjusted EBITDA projected to rise to $180 million to $220 million, reflecting confidence in future market opportunities.
See More
Alvotech Reports Significant Growth in 2025 Financials
- Significant Revenue Growth: Alvotech reported total revenue of $173.2 million for Q4 2025, reflecting a 12.9% increase year-over-year, indicating strong performance in the biosimilar market and potential for future market share expansion.
- Profitability Improvement: The company achieved a net profit of $27.92 million in 2025, a substantial turnaround from a loss of $231.86 million the previous year, showcasing successful cost control and market strategies that enhance investor confidence.
- EBITDA Surge: Adjusted EBITDA rose to $137.1 million in 2025, up 26.6% from the prior year, reflecting improved operational efficiency and optimized product mix, which is expected to support future profitability.
- Optimistic Outlook: Alvotech reaffirmed its 2026 revenue guidance of $650 to $700 million, anticipating double-digit sales growth, and plans to receive FDA approval for four Biologics License Applications by late 2026, further solidifying its market position.
See More
Alvotech Q4 Revenue Exceeds Expectations
- Revenue Growth: Alvotech reported Q4 revenue of $173 million, reflecting a 13% year-over-year increase that surpassed market expectations by $13.07 million, indicating strong performance in the biosimilars market and reinforcing its market position.
- Adjusted EBITDA Performance: The company achieved an adjusted EBITDA of $69 million with a gross margin of 66%, demonstrating significant progress in cost control and operational efficiency, thereby enhancing its profitability.
- Product Approval Milestone: AVT05 received approval as a biosimilar to Simponi in the UK and European Economic Area, which will open new revenue streams for the company and strengthen its competitive edge in the biopharmaceutical sector.
- Positive Market Reaction: Despite FDA delays impacting Alvotech, positive market feedback on its biosimilar data has driven stock price increases, reflecting investor confidence in the company's future growth potential.
See More
Alvotech to Release Q4 and Full Year 2025 Results
- Earnings Release Schedule: Alvotech will announce its Q4 and full year 2025 financial and operational results on March 18, 2026, after U.S. market close, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call with a live Q&A on March 19, 2026, at 08:00 EST, aimed at enhancing investor engagement and addressing market concerns.
- Product Line Overview: Alvotech has five biosimilars approved and marketed in multiple global markets, targeting autoimmune disorders and eye diseases, demonstrating its competitiveness and market demand in the biosimilar sector.
- Strategic Partnership Network: The company has established a network of strategic commercial partnerships across the U.S., Europe, Japan, China, and other Asian countries, aiming to leverage local expertise to expand its market reach and enhance global operational capabilities.
See More
Alvotech Under Investigation for Securities Law Violations
- FDA Response Letter: Alvotech received a Complete Response Letter (CRL) from the FDA on November 3, 2025, regarding its biologics license application for AVT05, stemming from a failed facility inspection in July 2025, indicating significant compliance issues that could hinder future product launches.
- Significant Stock Decline: Following the CRL, Alvotech's stock plummeted from $7.65 per share on October 31, 2025, to $5.03 on November 3, 2025, marking a 34.25% drop, which reflects market concerns about the company's outlook and a substantial loss of investor confidence.
- Ongoing Legal Investigation: Kirby McInerney LLP is conducting an investigation on behalf of Alvotech investors to determine potential violations of federal securities laws; although no lawsuit has been filed yet, this inquiry could lead to future legal actions that may impact the company's reputation and financial health.
- Investor Rights Protection: The law firm encourages all investors who purchased or acquired Alvotech securities to reach out to discuss their rights, demonstrating a commitment to investor protection and potentially providing avenues for compensation for affected shareholders.
See More
Alvotech Increases Share Capital by $125,000
- Share Capital Increase: Alvotech successfully raised its share capital by $125,000 through the issuance of 12.5 million ordinary shares, enhancing its capital structure to support future growth.
- Subsidiary Shareholding: Alvotech Manco ehf. subscribed to all newly issued shares at $5.2 per share, holding 4.7% of the company, reflecting confidence in Alvotech's future prospects.
- Stable Outstanding Shares: While total issued shares increased from 334,038,147 to 346,538,147, the number of outstanding shares remains unchanged at 330,284,142, ensuring market stability.
- Purpose of Equity Financing: The share issuance aims to replenish the treasury shares reduced due to the lending of ordinary shares, ensuring the company can meet its financial obligations and enhancing financial flexibility.
See More
Alvotech Q4 2025 Earnings Call Highlights
- Financial Performance Boost: In Q4 2025, total revenues reached $173 million, a 13% year-over-year increase, with licensing revenues comprising 75%, driving gross margin up to 66% and adjusted EBITDA to $69 million, showcasing success in capital market transactions.
- Pipeline Expansion: Alvotech currently has 30 biosimilars in development and plans to establish a second manufacturing site with a U.S.-based CMO partner to enhance supply chain flexibility and resilience, ensuring future product availability in the market.
- Market Expansion Strategy: The collaboration with Teva to launch Selarsdi marks the company's second biosimilar launch in the U.S., while approvals for golimumab, denosumab, and aflibercept across Europe, the UK, and Japan further broaden market reach.
- Optimistic Outlook: Management reaffirmed the 2026 revenue guidance of $650 million to $700 million, expecting continued double-digit sales growth, with adjusted EBITDA projected to rise to $180 million to $220 million, reflecting confidence in future market opportunities.
See More
Alvotech Reports Significant Growth in 2025 Financials
- Significant Revenue Growth: Alvotech reported total revenue of $173.2 million for Q4 2025, reflecting a 12.9% increase year-over-year, indicating strong performance in the biosimilar market and potential for future market share expansion.
- Profitability Improvement: The company achieved a net profit of $27.92 million in 2025, a substantial turnaround from a loss of $231.86 million the previous year, showcasing successful cost control and market strategies that enhance investor confidence.
- EBITDA Surge: Adjusted EBITDA rose to $137.1 million in 2025, up 26.6% from the prior year, reflecting improved operational efficiency and optimized product mix, which is expected to support future profitability.
- Optimistic Outlook: Alvotech reaffirmed its 2026 revenue guidance of $650 to $700 million, anticipating double-digit sales growth, and plans to receive FDA approval for four Biologics License Applications by late 2026, further solidifying its market position.
See More
Alvotech Q4 Revenue Exceeds Expectations
- Revenue Growth: Alvotech reported Q4 revenue of $173 million, reflecting a 13% year-over-year increase that surpassed market expectations by $13.07 million, indicating strong performance in the biosimilars market and reinforcing its market position.
- Adjusted EBITDA Performance: The company achieved an adjusted EBITDA of $69 million with a gross margin of 66%, demonstrating significant progress in cost control and operational efficiency, thereby enhancing its profitability.
- Product Approval Milestone: AVT05 received approval as a biosimilar to Simponi in the UK and European Economic Area, which will open new revenue streams for the company and strengthen its competitive edge in the biopharmaceutical sector.
- Positive Market Reaction: Despite FDA delays impacting Alvotech, positive market feedback on its biosimilar data has driven stock price increases, reflecting investor confidence in the company's future growth potential.
See More
Alvotech to Release Q4 and Full Year 2025 Results
- Earnings Release Schedule: Alvotech will announce its Q4 and full year 2025 financial and operational results on March 18, 2026, after U.S. market close, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call with a live Q&A on March 19, 2026, at 08:00 EST, aimed at enhancing investor engagement and addressing market concerns.
- Product Line Overview: Alvotech has five biosimilars approved and marketed in multiple global markets, targeting autoimmune disorders and eye diseases, demonstrating its competitiveness and market demand in the biosimilar sector.
- Strategic Partnership Network: The company has established a network of strategic commercial partnerships across the U.S., Europe, Japan, China, and other Asian countries, aiming to leverage local expertise to expand its market reach and enhance global operational capabilities.
See More
Alvotech Under Investigation for Securities Law Violations
- FDA Response Letter: Alvotech received a Complete Response Letter (CRL) from the FDA on November 3, 2025, regarding its biologics license application for AVT05, stemming from a failed facility inspection in July 2025, indicating significant compliance issues that could hinder future product launches.
- Significant Stock Decline: Following the CRL, Alvotech's stock plummeted from $7.65 per share on October 31, 2025, to $5.03 on November 3, 2025, marking a 34.25% drop, which reflects market concerns about the company's outlook and a substantial loss of investor confidence.
- Ongoing Legal Investigation: Kirby McInerney LLP is conducting an investigation on behalf of Alvotech investors to determine potential violations of federal securities laws; although no lawsuit has been filed yet, this inquiry could lead to future legal actions that may impact the company's reputation and financial health.
- Investor Rights Protection: The law firm encourages all investors who purchased or acquired Alvotech securities to reach out to discuss their rights, demonstrating a commitment to investor protection and potentially providing avenues for compensation for affected shareholders.
See More
Alvotech Increases Share Capital by $125,000
- Share Capital Increase: Alvotech successfully raised its share capital by $125,000 through the issuance of 12.5 million ordinary shares, enhancing its capital structure to support future growth.
- Subsidiary Shareholding: Alvotech Manco ehf. subscribed to all newly issued shares at $5.2 per share, holding 4.7% of the company, reflecting confidence in Alvotech's future prospects.
- Stable Outstanding Shares: While total issued shares increased from 334,038,147 to 346,538,147, the number of outstanding shares remains unchanged at 330,284,142, ensuring market stability.
- Purpose of Equity Financing: The share issuance aims to replenish the treasury shares reduced due to the lending of ordinary shares, ensuring the company can meet its financial obligations and enhancing financial flexibility.
See More
